Analysis of the growth characteristics of a primary BALB/c IgG plasmacytoma

Spontaneously arising and chemically or virally induced tumors usually cannot be analyzed in the early stages of tumorigenesis. Growth characteristics of these tumors thus are not available and it is unkown whether their expansion at any stage is influenced by the immune system. We have developed the following strategy to evaluate possible deviations from exponential growth in initial stages when a tumor is not yet manifest and in order to overcome the two main objections against most experiments in tumor immunology: use of possibly selected transplantable tumors and high initial cell doses. BALB/c mice received 0.5 ml of Pristane intraperitoneally three times within 16 weeks. This treatment induces plasmacy‐tomas in 58% of the animals within I year. Mice were bled twice a week beginning with the 5th week after the last injection and sera were stored. Guinea‐pig anti‐idiotypic antibodies were raised against the IgG myeloma protein of a plasmacytoma developing in mouse 6‐15 and a radioimmunoassay was set up. Sera of mouse 6‐15 were then tested in retrospect for appearance and increase of the myeloma idiotype Id 6‐15. We followed this idiotype thus for 19 weeks from a concentration of about 10 μg/ml up to 3 mg/ml serum. Plasmacytoma 6‐15 cell growth was calculated from the Id 6‐15 levels. In early phases wave‐like fluctuations were found, possibly due to varying ratios of secretor to total plasmacytoma 6‐15 cells. This phase was followed by an exponential increase in secretor cell number. At no time was there evidence for anti‐idiotypic auto‐antibodies against Id 6‐15. The data are discussed in connection with possibly early activation of cellular components of the immune system.

[1]  B. Dieckgraefe,et al.  Lymphocyte surface membrane immunoglobulin in myeloma. III. IgA plasmacytomas induce large numbers of circulating, adult-thymectomy-sensitive, theta +, Lyt-1-2+ lymphocytes with IgA-Fc receptors. , 1982, Journal of immunology.

[2]  H. Haubeck,et al.  Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis. , 1982, Immunology.

[3]  B. Loveland,et al.  Which T cells cause graft rejection , 1982 .

[4]  V. Schirrmacher,et al.  High‐frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb) , 1982, International journal of cancer.

[5]  A. Abbas,et al.  Immunologic regulation of lymphoid tumor cells: model systems for lymphocyte function. , 1982, Advances in immunology.

[6]  M. Cohn,et al.  Tumorigenicity and lysis by natural killers , 1981, The Journal of experimental medicine.

[7]  B. Odermatt,et al.  Immunoregulation of Murine Myeloma Cell Growth and Differentiation; A Monoclonal Model of B Cell Differentiation 1 , 1979, Immunological reviews.

[8]  C. Frondoza,et al.  Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer. , 1979, Cancer Research.

[9]  B. Odermatt,et al.  Immunoregulation of murine myeloma: isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo. , 1979, Journal of immunology.

[10]  C. Jenkin,et al.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. , 1978, Immunochemistry.

[11]  R. Burton,et al.  Tumor immunity to murine plasma cell tumors. V. Demonstration of a unique tumor antigen that is not associated with the myeloma idiotype , 1978, International journal of cancer.

[12]  J. Russell,et al.  Periodic loss of reactivity of a myeloma tumor with cytotoxic thymus-derived lymphocytes. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Lynch,et al.  Specific, immunologic regulation of differentiation of immunoglobulin expression in MOPC-315 cells during in vivo growth in diffusion chambers. , 1977, Journal of immunology.

[14]  R. Lynch,et al.  Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation. , 1977, Journal of immunology.

[15]  R. Lynch,et al.  Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity. , 1977, Journal of immunology.

[16]  G. Klein,et al.  Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors: a lesson in contrasts. , 1977, Transplantation proceedings.

[17]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[18]  I. Witz,et al.  PROTECTIVE AND CELLULAR IMMUNE RESPONSES TO IDIOTYPIC DETERMINANTS ON CELLS FROM A SPONTANEOUS LYMPHOMA OF NZB/NZW F1 MICE , 1974, The Journal of experimental medicine.

[19]  J. Schrader,et al.  EFFECTOR CELL BLOCKADE A NEW MECHANISM OF IMMUNE HYPOREACTIVITY INDUCED BY MULTIVALENT ANTIGENS , 1974 .

[20]  P. Johnson,et al.  Suppression of Gross leukemia cell-surface antigens: a kind of antigenic modulation. , 1972, Journal of the National Cancer Institute.

[21]  M. Potter Immunoglobulin-producing tumors and myeloma proteins of mice. , 1972, Physiological reviews.

[22]  H. Eisen,et al.  Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Prehn The Immune Reaction as a Stimulator of Tumor Growth , 1972, Science.

[24]  T. Kindt,et al.  THE INHERITANCE OF INDIVIDUAL ANTIGENIC SPECIFICITIES OF RABBIT ANTIBODIES TO STREPTOCOCCAL CARBOHYDRATES , 1971, Journal of Experimental Medicine.

[25]  E. Kölsch An alteration of secreted immunoglobulin in serum. , 1967, Journal of immunology.